Intensive Care in General
Conditions
Brief summary
The storage and use of biomaterial samples is an important requirement for accompanying research and the acquisition of new knowledge to improve prognosis and therapy. Biobanking is explicitly recommended in official guidelines. In order to preserve the biomaterial, the patient must consent to the removal, transfer and storage of the biomaterial separately from the consent to the register. The biomaterial is taken at times at which a blood or urine sampling takes place anyway in the clinical routine. Therefore no additional interventions are necessary.
Detailed description
The storage and use of biomaterial samples is an important requirement for accompanying research and the acquisition of new knowledge to improve prognosis and therapy. Biobanking is explicitly recommended in official guidelines. In order to preserve the biomaterial, the patient must consent to the removal, transfer and storage of the biomaterial separately from the consent to the register. The biomaterial is taken at times at which a blood or urine sampling takes place anyway in the clinical routine. Therefore no additional interventions are necessary. Sample volumes are defined as follows: * Peripheral blood: up to a total of 150 ml distributed to a maximum of 10 morning blood samples (approximately 15 ml blood per blood sample) during the inpatient stay in the intensive care unit (fixed times are admission and discharge of the intensive care unit) * Urine: a total of up to 200 ml of catheter urine distributed to a maximum of 10 morning withdrawals during inpatient stays in the intensive care unit (defined times are admission and discharge from the intensive care unit)
Interventions
OTHERBiological Database
Biological Database
Sponsors
RWTH Aachen University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients after admission to the intensive care unit * 18 years or older * signed informed consent
Exclusion criteria
* No
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Interleukin 6 value [nmol/l] | 10 days | Record of clinically relevant parameters |
| Interleukin 10 [nmol/l] | 10 days | Record of clinically relevant parameters |
| Adrenomedullin value [nmol/l] | 10 days | Record of clinically relevant parameters |
| Tumornekrosefaktor alpha [nmol/l] | 10 days | Record of clinically relevant parameters |
| Procalcitonin [nmol/l] | 10 days | Record of clinically relevant parameters |
Countries
Germany
Contacts
Primary ContactChristina Kalvelage, M. Sc.
Backup ContactChristian Stoppe, Dr. med.
Outcome results
None listed